NeuroVive and Sihuan Pharmaceutical to Develop and Commercialise CicloMulsion® and NeuroSTAT® for Cardio- and Neuroprotection in China

NeuroVive and Sihuan Pharmaceutical to Develop and Commercialise CicloMulsion® and NeuroSTAT® for Cardio- and Neuroprotection in China PR Newswire BEIJING and LUND, Sweden, November 20, 2012 BEIJING and LUND, Sweden, November 20, 2012 /PRNewswire/ -- NeuroVive, the leading mitochondrial medicine company, today announces a collaboration agreement with Sihuan Pharmaceutical Holdings Group Ltd. for the development and commercialisation in China of NeuroVive's most clinically advanced products CicloMulsion® and NeuroSTAT®. Sihuan Pharmaceutical is one of the largest domestic pharmaceutical companies in China and the market leader in the fast-growing Chinese cardio-cerebral vascular (CCV) drugs market. The agreement was entered into by Sihuan Pharmaceutical through its wholly-owned subsidiary Sun Moral International (HK) Ltd. and by NeuroVive through its subsidiary NeuroVive Pharmaceutical Asia Ltd. CicloMulsion® and NeuroSTAT® are in clinical development by NeuroVive for the treatment of heart reperfusion injury after stenting and traumatic brain injury respectively. These are indications of huge medical need for which there are currently no approved pharmaceutical treatment options. Both products act to prevent the death of mitochondria in damaged cells and the cascade of intracellular biochemical events that lead to secondary tissue damage following a traumatic injury.